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ABSTRACT 
Children with Neurofibromatosis Type 1 (NF1) may exhibit an incomplete clinical presentation, making difficult to 
reach a clinical diagnosis. A phenotypic overlap may exist with children with other RASopathies or with other 
genetic conditions if only multiple café-au-lait macules (CALMs) are present. The syndromes that can converge in 
these inconclusive phenotypes have different clinical courses. In this context, an early genetic testing has been 
proposed to be clinically useful to manage these patients. We present the validation and implementation into 
diagnostics of a custom NGS panel (I2HCP) for testing patients with a clinical suspicion of a RASopathy (n=48) 
and children presenting multiple CALMs (n=102). We describe the mutational spectrum and the detection rates 
identified in these two groups of individuals. We identified pathogenic variants in 21 out of 48 patients with clinical 
suspicion of RASopathy, with mutations in NF1 accounting for 10% of cases. Furthermore, we identified pathogenic 
mutations mainly in the NF1 gene, but also in SPRED1, in more than 50% of children with multiple CALMs, 
exhibiting a NF1 mutational spectrum different from a group of clinically diagnosed NF1 patients (n=80). An NGS 
panel strategy for the genetic testing of these two phenotype-defined groups outperforms previous strategies. 
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INTRODUCTION 
 
Neurofibromatosis Type 1 (NF1) is a neuro-cutaneous genetic disease with a birth incidence of 1:2500-1:30001 . It 
is characterized by a highly variable expressivity, in which multiple pigmented café-au-lait macules (CALMs) in 
the skin (>0,5cm in children; >1,5cm in adults) and multiple cutaneous neurofibromas affect almost all NF1 
individuals. Clinical criteria are normally fulfilled at the age of 82 although cutaneous neurofibromas are not 
developed until late teens3 turning out in inconclusive clinical diagnostic of NF1 in childhood. 
The presence of few skin CALMs at an early age is common among children4,5 but in multiple form could also be 
an indication of the presence of an inherited disease. The solely presence of 6 or more CALMs at early childhood 
constitutes a high risk for having NF1 and it is one of the main clinical criteria used6–8. However, multiple CALMs 
could also be indicative of other monogenic diseases, like some RASopathies or other syndromes like PTEN 
hamartoma tumor or Cowden syndrome (PHTS), Carney Syndrome or constitutive mismatch repair deficiency 
(CMMRD)4,5,9,10. 
The RASopathies constitute a clinically defined group of genetic conditions caused by germline mutations in genes 
that encode for components of the RAS/mitogen-activated protein kinase (MAPK) pathway. RASopathies include 
in addition to NF1: Noonan syndrome (NS), Noonan syndrome with multiple lentigines (NSML), Costello syndrome 
(CS), Legius Syndrome (LS), cardio-facio-cutaneos (CFC) syndrome and capillary malformation- arteriovenous 
malformation (CM-AVM)11. Each RASopathy exhibits a particular group of clinical manifestations, but due to the 
common underlying RAS/MAPK pathway deregulation, many of these conditions exhibit numerous overlapping 
phenotypic features, especially during early childhood (reviewed in12). Overlapping clinical manifestations include 
cutaneous, musculoskeletal, and ocular abnormalities; craniofacial dysmorphology; cardiovascular abnormalities; 
neurocognitive impairment; hypotonia; and increased risk of tumor development. NF1, Legius syndrome and CM-
AVM are caused by loss of function mutations in NF113, SPRED114 or RASA1 genes15, respectively. Others like 
Noonan, NSML and CFC syndromes exhibit genetic heterogeneity and together with Costello syndrome are caused 
by activating mutations in PTPN11, SOS1, RAF1, BRAF, KRAS, NRAS, SHOC2, BRAF, MAP2K1, MAP2K2, CBL, 
HRAS and RIT111,16–19. There are evidences that support other genes to be potentially associated with RASopathies 
(reviewed in17) like RASA220, A2ML121, PPPC1B22 SOS218, MRAS23, RRAS24 and LZTR118,25 although not all of them 
have the same gene-disease association supporting evidences26. 
 
At an early age, uncertain clinical diagnostics can emerge due to the presence of clinical manifestations that are 
common to NF1 as well as to other RASopathies or to other CALM-associated diseases. One example is the solely 
and combined presence of CALMs and skin fold freckling in LS and NF1 affected children27–29. Thus, children 
sharing a similar initial clinical presentation can bear mutations in different genes that predispose to very different 
clinical courses, that need to be managed in distinct ways. In this context, genetic testing can help in confirming a 
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clinical suspicion, facilitating an early adequate surveillance. For instance, genetic testing has been recommended 
to confirm NF1 in children fulfilling only pigmentary features of the diagnostic criteria30.  
Current comprehensive genetic testing strategies for these inherited diseases consist in either multi-gene panels or 
whole exome sequencing to solve problems like genetic heterogeneity or inconclusive clinical presentations31. In 
addition, due to the power and cost-effectiveness of NGS-based strategies and the demonstrated clinical utility32, 
inconclusive but suggestive clinical presentations are increasingly being accepted for genetic testing, accounting for 
a significant raise in genetic tests, especially at pediatric ages33. On the other side of the NGS coin, there is the 
exponentially growing number of identified genetic variants and the problem related to their pathogenicity analysis 
and interpretation. To standardize this process, the ACMG/ AMP guidelines34 are now widely adopted into clinical 
practice. However, these guidelines need to be adjusted according to the specificities of the genetic conditions being 
tested. In the case of RASopathies, an additional complication is the existence of diseases caused by both loss-of-
function and gain-of-function mutations. Recently, the ClinGen RASopathy Expert Panel has published new 
guidelines to improve gene-disease association and variant interpretation for Noonan, NSML, Costello, CFC and 
Noonan-like syndromes26,35. 
In this study, a new version of the I2HCP (ICO-IMPPC Hereditary Cancer Panel), a custom NGS-based diagnostic 
strategy36, was validated for its use in the molecular testing of all RASopathy-related genes. Once validated, the 
performance and implementation of this panel into routine diagnostics was evaluated for its use in the genetic testing 
of two groups of individuals sent to the diagnostics lab with an inconclusive clinical diagnostic: patients with a 
clinical suspicion of a RASopathy or children presenting multiple CALMs. We describe here a mutational spectrum 
for the two groups of individuals and demonstrate the appropriateness of our NGS panel in this clinical scenario. 
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MATERIALS &METHODS 
Subjects 
All procedures performed were in accordance with the ethical standards of the IGTP Institutional Review Board, 
who approved this study, and with the 1964 Helsinki declaration and its later amendments. Informed consent was 
obtained from all genetically diagnosed individuals that were included in the study. Genomic DNA from 259 
unrelated individuals were obtained from blood lymphocytes using standard protocols at three different centers: 
Department of Human Genetics KU Leuven; Department of Genetics, Microbiology and Statistics University of 
Barcelona and Genetics Testing Unit of IGTP. The 259 samples were grouped in four different sample sets: 1) 
RASopathy control group; 2) NF1 control group; 3) RASopathy-like group and 4) multiple CALM phenotype group. 
The RASopathy control set comprised 29 samples with variants in genes responsible for: Noonan syndrome, 
NSML, Costello, CFCS, NF1 and Legius syndrome, previously tested in KU Leuven and University of Barcelona. 
All samples had been genetically tested using pre-NGS workflows (cDNA and DNA Sanger sequencing). The 
RASopathy-like set consisted in 48 individuals with a clinical suspicion of a RASopathy-related syndrome 
(normally exhibiting facial dysmorphism and/or incomplete RASopathy-like traits), 16 of them previously tested in 
the University of Barcelona with no pathogenic mutation detected and 32 that arrived to the Genetics Testing Unit 
of IGTP. The NF1 control set contained 80 individuals fulfilling NF1 NHI criteria and the multiple CALM 
phenotype set comprised 102 children that presented more than 5 CALMs sent for testing at IGTP.  
Sample preparation and sequencing 
Library preparation and enrichment was performed as previously described36. Briefly, sample preparation was 
performed following the SureSelect XT protocol for MiSeq and enriched with custom I2HCP v2.2 library baits, 
which contained 135 genes including 22 genes involved in the RAS/MAPK pathway (Supplementary Table S1). 16 
equimolar indexed samples were pooled after capture and sequenced in a MiSeq (Illumina) with Reagent Kit v3, 
2x300. For each gene, we defined the regions of interest (ROIs)36. NGS data were processed and filtered according 
to the clinical indication using a custom data analysis pipeline as previously described 36. The validation analysis of 
I2HCP was performed blindly using the RASopathy control group.  
Validation by Sanger Sequencing 
Any ROI for all genes tested with at least one base below 30x was Sanger sequenced using standard protocols 
(primer sequences available upon request). All pathogenic variants and VUS, were also validated by Sanger 
sequencing. Human Genome Variation Society (www.hgvs.org) nomenclature guidelines were used to name the 
mutation at the DNA level and the predicted resulting protein. 
NF1 and SPRED1 additional mutational analysis  
In NF1 control patients and in individuals with multiple CALM phenotype (or NF1-associated tumors) that tested 
negative with the custom I2HCP panel, NF1 and SPRED1 genes were additionally tested by MLPA (SALSA MLPA 
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P122, P081, P082 and P295, following manufacturer’s instructions). In addition, negative MLPA cases and those 
with inconclusive NF1 variants were further analyzed at RNA level. The entire coding region of NF1 was amplified 
from cDNA in five overlapping PCR fragments. PCR products were analyzed by electrophoresis and Sanger 
sequencing. A schematic representation of the whole testing workflow is represented in Figure 1. 
 
Variant analysis and interpretation 
We evaluated SIFT, PolyPhen, CADD, PROVEAN, MutationTaster, REST, VEST3 and MetaSVM. Some of them 
had a pre-defined score, while for CADD, REST and VEST3 we used scores higher than 19, 0.5 and 0.8, 
respectively, to identify variants likely pathogenic. To evaluate in silico predictors we analyzed 45 recurrent NF1 
missense variants (≥3x) reported at https://databases.lovd.nl/shared/variants/NF1/unique and 502 unique missenses 
in NS, NSML, Costello, CFC -causing genes. RASopathy missense variants were selected if reported three or more 
times in NSEuronet database (http://nseuronet.com) as VUS, pathogenic or likely pathogenic variants; or reported 
as pathogenic or likely pathogenic in ClinVar. All missense variants detected in this study were classified using the 
combination of SIFT, PolyPhen, CADD, PROVEAN and MutationTaster. In addition, FoldX37 was used to evaluate 
the structural impact of each variant detected in this study on the corresponding protein  following developer’s 
instructions (http://foldxsuite.crg.eu). Values higher than 0.8 were considered to destabilize significantly the 
entropic energy of analyzed proteins. InterVar (http://wintervar.wglab.org/) was also used to classify all VUS 
identified following published recommendations38. 
Statistical analysis 
We tested whether the frequency of NF1 missense variants identified in the NF1 control and in the multiple CALM 
phenotype groups were different by applying a Chi square test using the Rscriptchisq.test function.  
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RESULTS 
Validation of the I2HCP NGS-panel for the genetic analysis of RASopathy genes 
The I2HCP strategy was first developed and validated for testing hereditary cancer genes, showing an analytical 
sensitivity of 98.4% and an analytical specificity of 100%36. Our I2HCP NGS panel also contained 22 known 
RASopathy associated genes. We first evaluated the performance of the I2HCP for the genetic testing of RASopathy 
syndromes. We analyzed a control group of 29 samples (Table 1) with 28 known mutations in 15 RASopathy genes: 
21 independent disease-causing mutations, 7 variants of unknown significance (VUS) and one case without a 
previously identified mutation. Although I2HCP custom panel v2.2 contained 135 genes, the genetic diagnostics 
strategy consisted in focusing the variant analysis only on those genes that have been consistently associated with 
the different RASopathy conditions (Supplementary Table S1). These genes included those recommended by the 
ClinGene RASopathy Expert Panel26, with the addition of NF1, SPRED1 and CBL11, and RASA1 for its association 
with CM-AVM11. The whole validation process was performed blindly. 
Each sample produced 3.1x106±0.67x106 SD paired reads, the mean depth of coverage was 530±116 SD, the 
coverage uniformity was of 35.2%±1.9% SD, and 98.9%±0.2% SD of the targeted bases were covered ≥30x 
(Supplementary Table S2, Supplementary Figure S1), very similar to the performance achieved for hereditary cancer 
genes36. The I2HCP panel identified all previously known variants present in the validation set, including 
substitutions and small insertions/deletions. No VUS or pathogenic variant was identified in the case in which no 
mutations were previously identified (Table 1). Therefore, considering the 28 known variants present in the 
validation set, there was an excellent performance of the I2HCP for testing RASopathy genes, preserving the same 
sensibility and specificity as reported previously in the validation of I2HCP panel for hereditary cancer testing36. 
 
Implementation of I2HCP into routine genetic testing for RASopathies and children with multiple CALMs 
We used the I2HCP-RASopathy subpanel to genetically test two groups of patients that at early childhood can have 
an overlapping presentation of clinical manifestations with NF1. These were basically grouped by phenotype: 1) 
individuals with a clinical suspicion of a RASopathy; 2) children with multiple CALMs. After clinical evaluation of 
individuals, sample preparation, sequencing and data analysis were performed for the whole set of 135 genes present 
in the panel. For the first group of patients, RASopathy genes (n=15) were further analyzed up to the level of variant 
interpretation (Supplementary Table S1). Similarly, only genes that have been consistently related with a CALM 
phenotype were analyzed for children with multiple CALMs in a stepwise manner (Figure 1, Supplementary Table 
S1): first NF1 and SPRED1, if necessary, other RASopathy genes, and finally, after a careful evaluation and 
following Suerink M et al. (2019) recommendations9, other genes related with a multiple CALM-phenotype4,9. 
Interpretation of missense variants in RASopathy genes 
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In order to classify missense variants in a consistent manner, we followed the recommendations of the ClinGen's 
RASopathy Expert Panel35. For genes not evaluated by this panel but included in this study we followed the 
ACMG/AMP guidelines34 (Supplementary Table S6). Among the criteria for the interpretation of variants, 
guidelines require the agreement of the in silico programs used. To establish the best in silico program combination 
for analyzing RASopathy genes, we first compiled two independent control data sets. They consisted in a list of 45 
pathogenic or likely pathogenic missense variants for NF1 (LOVD NF1 database); and 502 variants from 
NSEuroNet database and ClinVar, for other RASopathy genes. We then evaluated the performance of three different 
in silico algorithm combinations with these two data sets. The first two included: SIFT, PolyPhen and CADD in one 
combination, and SIFT, PolyPhen, CADD, PROVEAN and MutationTaster in the other. Using both data sets, we 
found that more than 80% of pathogenic and likely pathogenic variants had a total concordance in both combinations, 
38 out of 45 (84%) for NF1 (Supplementary Table S2) and 482 out of 502 (96%) for the other RASopathy genes 
(Supplementary Table S3). The results obtained using the 3-and 5-algorithm combinations were exactly the same 
and performed slightly better than previous findings using ClinVar data39. The third combination included three 
high-performance algorithm predictors: REVEL, VEST3 and MetaSVM. In this case, the rate of concordance 
between all three algorithms was of 36% (16 out of 45) for NF1 dataset and 59% (309 out of 521) for RASopathy 
dataset (Supplementary Table S2 and Table S3), performing worse than previously described39. Therefore, we chose 
the 5-algorithm combination for the interpretation of missense variants in NF1 and other RASopathy genes. 
Using this algorithm, we still had a fair percentage of variants classified as VUS. To try improving their 
classification, we explored the possibility of using FoldX, a structure-energy-based predictor tested previously in 
the context of RASopathies37, and InterVar, a clinical semi-automatic interpreter of genetic variants based on 
ACMG/AMP guidelines for variant classification38. The information provided by FoldX was very interesting due to 
its complementarity, but the absence of 3D protein structures for a significant number of RASopathy gene products 
or domains limited its use. Furthermore, a fair proportion of pathogenic or likely pathogenic variants were classified 
as VUS by InterVar. In our hands, none of them added utility regarding variant interpretation in a routine diagnostics 
setting. 
Testing RASopathy-like patients 
A total of 48 patients composed the RASopathy-like set. Overall the I2HCP diagnostics strategy allowed to detect a 
disease-causing variant in about 44% of the cases (n=21/48). In addition, in 12% of the individuals (n=6) a VUS in 
one of the interrogated genes was identified. About 44% of the cases were negative after using the NGS RASopathy 
panel (n=21) (Figure 2A, Supplementary Table S4). Sixteen out of 48 cases of the RASopathy set had previously 
been tested for a few genes causing Noonan and Costello syndromes, and represented patients that tested negative 
with previous approaches). Of those, we were able to detect a pathogenic variant in 5 cases (31%, 5/16) and one 
VUS (6%) in another individual. The remaining 32 were genetically analyzed for the first time. In this group, 16 
disease-causing mutations were identified (50%) and 5 VUS (16%). 11 patients (34%) tested negative for all 
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RASopathy genes using the NGS-I2HCP panel strategy (Figure 2B). However, among the individuals that tested 
negative, we identified a deleterious PTEN mutation in two patients. In both cases, patients exhibited some clinical 
manifestations related to RASopathies but none of them fulfilled clinical criteria for any particular condition. All 
together, these results showed that I2HCP strategy exhibit a good diagnostics yield outperforming previous single 
gene-based strategies. 
Mutational spectrum by phenotype 
Some patients of the RASopathy set (n=18) arrived to the genetic diagnostics lab with a defined clinical suspicion 
of NS, NSML, CFCS or CM-AVM, supported by their clinical record, while others (n=30) arrived with an 
inconclusive clinical diagnostic and where referred as RASopathy-like (Supplementary Table S4). We analyzed the 
mutational spectrum for each specific suspected condition, and for the RASopathy-like group (Figure 3, 
Supplementary Table S4). Among patients with a suspicion of a specific condition (n=18), 5 tested negative (28%), 
10 carried a pathogenic mutation (55%) and 3 carried a VUS (17%). Mutated genes matched their corresponding 
conditions, given the known genetic heterogeneity present in RASopathies. The only exceptions were two 
independent pathogenic variants identified in SPRED1 and NF1 in two patients of the NS group. The patient with 
the SPRED1 mutation was 22yo when tested and due to his/her facial traits was suspected to have NS. The patient 
with the NF1 mutation was a child first diagnosed at the age of 10 months with a clinical presentation that resembled 
a RASopathy without CALMs. 
The mutational spectrum in the RASopathy-like group (Figure 3, inconclusive phenotype) was similar to the one 
considering the whole RASopathy set (Figure 2A) being NF1, PTPN11 and RAF1 the genes concentrating most of 
the disease-causing mutations identified. Among the patients that tested negative in this group, there were the two 
individuals with a pathogenic mutation in PTEN. 
If disease-causing mutations and VUS were considered together, NF1 was the gene with more genetic variants 
identified (n=7) in the RASopathy-like group, even higher than PTPN11 (n=5) (Figure 2B), although any bias in the 
selection of individuals arriving to our testing unit could greatly influence this picture. Within those patients with a 
clinical suspicion of a RASopathy and an NF1 mutation, we realized that two carried a pathogenic variant in NF1 
but also bore a missense variant classified as VUS at the NF1 GRD domain (patients 469 and 711) (Supplementary 
Table S4). Both were children exhibiting Noonan-like facial dimorphism, ptosis, macrocephaly, developmental 
delay, and learning problems among other RASopathy features. Another patient of the RASopathy-like group 
(patient 464) carried two missense variants at RIT1 in trans, one pathogenic and the other one classified as VUS, 
and showed a severe RASopathy-like phenotype (Supplementary Table S4). We were not able to perform 
segregation analysis for any of the VUS identified in these three patients. 
Testing children with multiple CALMs 
The I2HCP NGS panel allowed the genetic testing of multiple-CALM phenotype in a stepwise manner as mentioned 
above (Figure 1). We analyzed NF1 and SPRED1 genes in 102 children that arrived from different centers to our 
This article is protected by copyright. All rights reserved.
genetic testing unit with clinical suspicion of NF1 or LS due to the presence of multiple CALMs. None of them had 
been previously genetically analyzed and represented sporadic cases. We further divided the 102 children in three 
subsets: children exhibiting ≥6 CALMs as the only clinical manifestation (n=71); children with multiple CALMs 
and another clinical manifestations not being an NF1 NIH clinical criteria (facial dimorphism, cognitive disorders 
or tumors not related to NF1) (n=26), and finally, a small group of 5 infants with multiple CALMs and skin-fold 
freckling. In addition, we also analyzed 80 patients fulfilling NF1 NIH criteria by the presence of multiples CALMs 
(with or without skin-fold freckling) and at least one additional NF1 NIH criteria that we used as a control group for 
an NF1 phenotype. In all 182 cases we applied the I2HCP NGS-based strategy for NF1 and SPRED1 analysis 
followed by MLPA of both genes and RNA-based (cDNA) analysis of NF1, when required.  
As a baseline for comparison, we first analyzed the performance of the new testing workflow in the group fulfilling 
NF1 NIH clinical criteria (n=80) (Figure 1, Supplementary Figure S2). The use of the I2HCP panel alone detected 
a potentially pathogenic NF1 variant in 71 individuals (71/80; ~89%). In 64 cases (64/80; 80%) the variant was 
conclusively pathogenic and for seven cases bearing intronic or missense variants, additional RNA analysis was 
required to clarify their pathogenicity. Five of the seven variants altered the correct NF1 splicing (5/80, 6.25%) and 
the two remaining ones were classified as VUS. Segregation analysis of these VUS did not clarify their 
pathogenicity. MLPA was further performed in nine cases in which no variant was identified by I2HCP NGS 
analysis. We identified two copy number variation (CNV) mutations (2/80; 2.5%). Finally, RNA-based analysis of 
the seven remaining negative cases identified four independent deep intronic mutations affecting the correct NF1 
splicing (4/80; 5%). In three cases (3/80; 3.75%) we were unable to identify a disease-causing mutation, although 
mosaicism cannot be discarded (Figure 4A, Supplementary Figure S2 and Table S5). In summary, I2HCP panel 
alone identified a pathogenic variant in 69/80 cases (86%), although five cases required additional RNA-based 
analysis. MLPA analysis identified two further cases and RNA analysis was required to identify four additional 
deep-intronic mutations. Two variants were classified as VUS (2.5%) and three cases tested negative (3.75%). The 
use of the I2HCP panel helped in simplifying the whole testing process and had a good performance, similar to 
previous comprehensive strategies, although a combination of DNA and RNA-based analysis was still necessary to 
reach a high sensitivity. 
We then analyzed the other cases with ≥6 CALMs, grouped by phenotype. The percentage of positive tests varied 
among groups . Fifty-two percent (37/71) of children exhibiting only ≥6 CALMs carried a disease-causing variant 
and in addition we detected a VUS in 12% of them (9/71) (Figure 4A; Supplementary Table S5). In the group of 
children with ≥6 CALMs and one sign not related to NF1, the percentage of positive tests was of 38% (10/26) and 
in ~12% of cases a VUS was identified (3/26). A pathogenic mutation in the NF1 gene was identified in all cases 
(n=5) exhibiting ≥6 CALMs and skin-fold freckling as the only clinical manifestations (Figure 4A). All non-
conclusive cases (negative cases and cases with VUS for NF1 and SPRED1) from the different groups were analyzed 
for the rest of genes present in the RASopathy panel. In addition, in the specific individuals with ≥6 CALMs and a 
non-NF1 tumor present, genes causing CMMRD were analyzed. No additional genetic variants were identified. 
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NF1 mutational spectrum.  
The new NF1 genetic testing workflow identified a genetic variant in 96% of patients fulfilling NF1 NIH criteria by 
the presence of ≥6 CALMs and two additional NIH criteria (in 92% of cases a conclusive pathogenic variant). In 
this group, we detected NF1 variants spread over the entire coding region of NF1, including nonsense (32.5%), 
frameshift (27.3%), missense variants (18.2%, two of them VUS), NF1 microdeletions (1.3%), intragenic CNV 
involving several exons (1.3%), and variants in canonic and non-canonic splice sites and deep intronic mutations 
(19.4%) (Figure 4B, Supplementary Table S5). 70 out of these 77 variants were unique in our set. The percentage 
of each mutation type was slightly different but in accordance to other published results40. Since we did not test the 
effect of all mutations at RNA level, the slight discrepancy regarding splicing mutations could come from the fact 
that different types of pathogenic mutations at DNA level can cause splicing defects41,42. Any bias in the NF1 
population analyzed would also affect the frequency of the different mutation types. Remarkably, the different 
frequency of NF1 mutation types detected in the cohort of children with ≥6 CALMs (n=102) compared to the control 
NF1 group was statistically significant, consisting in a lower proportion of nonsense and frameshift mutations and 
a higher proportion of missense variants, both, clearly pathogenic and VUS (Figure 4B, Supplementary Table S5).  
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DISCUSSION 
In this study, we first validated the use of the I2HCP V2.2 diagnostic strategy, a custom NGS-based panel of 135 
genes and an analysis pipeline already validated for hereditary cancer testing36, for the genetic diagnostics of patients 
with any RASopathy syndrome. The panel included 22 RASopathy-related genes. However, for its use in genetic 
testing, we considered only the 11 RASopathy genes recommended by the ClinGen RASopathy Expert Panel26 
together with NF1, SPRED1, CBL and RASA1. The use of a smaller gene panel could be more cost-effective, 
however, the I2HCP was designed to fit our global diagnostics activity and provides a greater capacity of analyzing 
uncertain phenotypes potentially involving other genes included in this panel. The custom nature of I2HCP provides 
the flexibility for rapidly incorporating new recommended genes, like PPP1CB and MRAS genes.  
The sensitivity and specificity of I2HCP v2.2 to detect alterations in RASopathy genes using a control group of 29 
RASopathy patients were similar to the ones reported for hereditary cancer genes (>99%)36. When applied to the 
RASopathy-like group (48 individuals), in 60% of the cases a clear pathogenic mutation (44%) or a VUS (12%) 
were identified (in 66% of the patients if only those tested for the first time were considered). The gene-specific 
frequencies detected were consistent with previous reports (NSEuronet) although the percentage of negative cases 
was slightly greater than reported43. However, the overall performance of the I2HCP testing strategy partially 
depended on the clinical evaluation of the patients referred for testing (see M&M; Supplementary Table S4). As an 
example, in the RASopathy-like group we detected two patients with a pathogenic PTEN mutation. Nevertheless, 
this panel-based strategy outperformed previous testing single-gene strategies, since it was able to detect pathogenic 
variants in 5 individuals from a group of 16 patients that had been genetically tested previously. 
If we just consider the testing for NF1 mutations, the use of the I2HCP panel helped in simplifying the whole testing 
algorithm and experimental procedures while preserving a good performance and diagnostic yield compared with 
pre-NGS diagnostic strategies. I2HCP mapping and variant calling constrictions avoided interference of NF1 
pseudogenes36. However, we consider necessary the additional use of a CNV detection assay and an RNA-based 
analysis in the overall testing strategy. The use of the I2HCP panel alone identified a pathogenic variant in 86% of 
the NF1 control group (69/80 cases) although RNA-analysis was necessary for the correct assessment of functional 
impact in 5 cases. In addition, RNA-based analysis was indispensable to detect four additional cases bearing deep-
intronic mutations. Bioinformatic CNV analysis using panel-based NGS data has greatly improved. However, in our 
hands, the CNV analysis of the NF1 gene using panel data is still quite variable and is being validated for diagnostic 
purposes. Thus, all CNV analysis in the present work were performed by MLPA.  
In the cohort of RASopathy-like patients, we detected seven patients with a NF1 mutation, thus with 
Neurofibromatosis Type 1. Most of them exhibited a Noonan-like facial dimorphism with or without other 
RASopathy clinical manifestations, and some of them presented CALMs like in Neurofibromatosis-Noonan 
syndrome (NF-NS, OMIM:#601321). Pathogenic variants along the NF1 gene, including in-frame mutations in the 
GRD, have been associated with NFNS44. These findings highlight the difficulty of clinically discriminating among 
RASopathy conditions at pediatric ages and supports the recommendation of analyzing the classical RASopathy 
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gene set together with NF1 and SPRED1 genes at the same time in order to increase the number of positive genetic 
tests in patients with a clinical suspicion of a RASopathy44,45.  
The presence of ≥6CALMs of 0.5cm could be indicative of NF1 but also of LS, CMMRD or other genetic conditions. 
In the analyzed cohort of 102 children with multiple CALMs, we only detected mutations in the NF1 and SPRED1 
genes. Among the 102 children, the percentage of NF1 and LS patients were variable among the distinct subgroups 
established according to the presence or not of other clinical symptoms, but overall similar to previous reports28,46. 
In cases that tested negative for NF1 and SPRED1 mutations, we did not find alterations in other RASopathy genes 
in patients with ≥6CALMs and facial dimorphism or cognitive disorders, neither in MMR genes in the cases where 
this possibility was considered. Our results support previous recommendations for testing children with multiple 
CALMs (with or without other symptoms) in a stepwise manner9,30,47. In cases with CALMs and pediatric cancers 
or familial history of cancer, the genetic testing recommendations include the analysis of cancer predisposition 
genes48. In these situations, the use of a panel such as the I2HCP could be convenient due to the possibility to analyze 
all recommended genes at once.  
The NF1 mutational spectrum identified in the group of children with ≥6CALMs not fulfilling NF1 NIH criteria was 
different from the one present in the control NF1 group (Figure 4 B). In the former group, the proportion of truncating 
mutations was lower than the control NF1 group. At the same time, the percentage of missense variants (both 
pathogenic and VUS) was higher, opening the possibility that these mutations could represent hypomorphic alleles 
generating incomplete or mild NF1 phenotypes. A prospective follow up of this group of patients could provide 
insight into this possibility and contribute to a better genotype-phenotype understanding. 
Using the I2HCP strategy in hereditary cancer patients, we previously identified patients containing a complex 
variation landscape in herereditary cancer genes co-existing with the disease-causing mutation36. This was not the 
case for RASopathy-like individuals in RAS/MAPK pathway genes, except in three patients in which in addition to 
a pathogenic variant, a missense variant was detected in the same disease-causing gene (Supplementary Table S4 
and Table S5). All three patients presented a complex clinical presentation, although the functional impact of these 
two co-existing variants in the same gene is unknown and further studies would be required to reach any conclusion. 
We followed the ACMG/AMP guidelines including modifications suggested by the ClinGen's RASopathy Expert 
Panel35 for variant interpretation. ACMG/AMP guidelines recommend the agreement of all in silico programs tested 
for using them as supportive evidence. In our hands, SIFT, PolyPhen, CADD, PROVEAN and MutationTaster had 
the highest ratio of true concordance when they were combined, seeming the most suitable for the assessment of 
RASopathy-related variants. In any case, we found necessary to perform also a manual curation, in addition to in 
silico predicting algorithms, along the process of variant interpretation.  
We also explored the possibility of using FoldX and InterVar for variant classification but, in our hands, none of 
them added utility regarding variant interpretation in a genetic testing context. For the whole set of 71 missense 
variants detected in both sets of patients only 25 of them (35%) had an accurate 3D protein structure containing the 
variant we wanted to evaluate (Supplementary Table S6). In addition, 41% of pathogenic or likely pathogenic 
This article is protected by copyright. All rights reserved.
variants classified following our guidelines were classified as VUS by InterVar, exhibiting a poor correlation for its 
use.  
We have validated the use of the custom I2HCP NGS panel for the routine genetic diagnostics of RASopathy-related 
genes. We have shown the utility of this strategy for testing children with an inconclusive clinical suspicion of a 
RASopathy and children with multiple CALMs. An NGS panel strategy outperforms previous testing strategies for 
these two phenotype-defined groups. We identified pathogenic variants in the NF1 gene in several inconclusive 
RASopathy cases. In addition, we identified pathogenic variants in NF1 and SPRED1 in more than 50% of children 
with ≥6 CALMs, exhibiting an NF1 mutational spectrum different from NF1 patients fulfilling NF1 NIH criteria. 
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TABLES: 
Table 1: Validation of the I2HCP NGS panel for RASopathy testing. 
Footnotes: depth: depth of coverage; freq: variant frequency; PAT: pathogenic; VLP: variant likely pathogenic; 
VUS: variant of unknown significance 
FIGURE LEGENDS 
 
Figure 1: Genetic testing workflow. Schematic representation of techniques used, genes analyzed and 
clinical manifestations considered. 
Figure 2: Analysis of the Rasopathy-like group. The I2HCP diagnostics strategy allowed to detect a 
disease-causing variant in about 44% of the cases. A) Pie chart showing the percentage of positive cases, 
negative (light grey) and individuals with variants of unknown significance (VUS) (light blue). Positive 
cases are decomposed in the relative frequencies of pathogenic or likely-pathogenic variants for each 
RASopathy gene; B) Diagram showing the diagnostic yield and mutation frequencies for samples that 
had or had not been previously tested by pre-NGS methods. Dark blue indicates pathogenic or likely 
pathogenic variants detected, light blue VUS detected and light grey indicates negative cases.  
Figure 3: Mutational spectrum of RASopathy-like individuals. Eighteen RASopathy-like patients 
(18/48) had a defined clinical suspicion of NS, NSML, CFCS or CM-AVM while 30 (30/48) had an 
inconclusive clinical diagnostic before genetic testing. For each group, the number of patients, the number 
of diagnostics with a pathogenic or likely pathogenic variant detected (+Test) and the number and 
frequency of mutations per gene is indicated.  
Figure 4: Analysis of individuals with Multiple CALMs. Two groups of individuals were compared: 
an NF1 control set containing 80 individuals fulfilling NF1 NHI criteria, and a group of 102 children that 
presented more than 5 CALMs constituting the multiple CALM phenotype set. This latter set was further 
divided in three subsets depending on the presence (or not) of other clinical signs. A) Description of the 
mutational spectrum identified. Inserted pie charts indicate the percentage of individuals with identified 
variants per gene. B) Description of the NF1 mutational spectrum identified in each set and subset of 
individuals. C) Chi square test results evaluating the frequencies of NF1 missense variants in the NF1 control and 
in the multiple CALM phenotype groups. 
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461 HRAS NM_005343.2 c.34G>A 2 p.Gly12Ser chr11:534289 899 52,23 rs104894229 Costello: Pathogenic PAT 466x VLP
466 PTPN11 NM_002834.3 c.1391G>C 12 p.Gly464Ala chr12:112926258 446 45,29 rs121918469 Noonan & LEOPARD: Pathogenic PAT 8x PAT
467 BRAF NM_004333.4 c.770A>G 6 p.Gln257Arg chr7:140501302 493 50,61 rs180177035 CFC: Pathogenic PAT 67x PAT
473 BRAF NM_004333.4 c.1783T>C 15 p.Phe595Leu chr7:140453152 353 46,18 PAT 7x PAT
475 HRAS NM_005343.2 c.35G>C 2 p.Gly12Ala chr11:534288 921 49,89 rs104894230 Costello: Pathogenic - PAT
477 BRAF NM_004333.4 c.770A>G 6 p.Gln257Arg chr7:140501302 388 48,71 rs180177035 Noonan & CFC: Pathogenic PAT 67x PAT
483 MAP2K1 NM_002755.3 c.389A>G 3 p.Tyr130Cys chr15:66729181 885 50,51 rs121908595 CFC: Pathogenic PAT 31x CFC PAT
484 BRAF NM_004333.4 c.1574T>A 13 p.Leu525Gln chr7:140476832 361 43,49 PAT 2x VUS
489 BRAF NM_004333.4 c.1801A>C 15 p.K601Gln chr7:140453134 585 45,3 Noonan: Pathogenic PAT 3x CFC VLP
525 SPRED1 NM_152594.2  c.1149_1152delAGAG 7 p.Gly385Ilefs chr15:38643679 519 47,59 PAT 15x PAT
543 PTPN11 NM_002834.3 c.836A>G 7 p.Tyr279Cys chr12:112910827 162 52,47 rs121918456 Noonan & LEOPARD: Pathogenic 75x PAT
544 PTPN11 NM_002834.3 c.922A>G 8 p.Glu308Asp chr12:112915523 390 45,38 rs28933386 Noonan & LEOPARD: Pathogenic 0,0001 0,0000184 INCONGRUOUS 195x PAT
545 SOS1 NM_005633.3 c.2536G>A 16 p.Asp846Lys chr2:39234309 314 46,82 Noonan: Pathogenic INCONGRUOUS 26x PAT
546 SOS1 NM_005633.3 c.806T>C 6 p.Mey269Thr chr2:39278343 441 48,75 Noonan: Pathogenic PAT 20x PAT
547 KRAS NM_033360.2 c.179G>T 3 p.Gly60Val chr12:25380279 188 46,28 PAT - VLP
548 RAF1 NM_002880.3 c.1472C>T 14 p.Thr491Ile chr3:12627244 457 46,61 rs80338799 LEOPARD: Pathogenic PAT 2x VLP
549 NF1 NM_000267.3 c.3508_3509insA 27 p.His1170fs chr17:29560031 403 49,38 - PAT
550 RIT1 NM_006912 c.284G>C 5 p.Gly95Ala chr1:155874247 658 46,96 Noonan: Pathogenic PAT 10x PAT
551 No previous variant detected -
552 SOS2 NM_006939.2 c.1127C>G 9 p.Thr376Ser chr14:50628269 804 51,37 INCONGRUOUS 9x VLP
553 LZTR1 NM_006767.3 c.2090G>A 18 p.Arg697Gln chr22:21350272 728 44,84 0,00003681 PAT - VUS
554 NRAS NM_002524.4 c.101C>T 2 p.Pro34Leu chr1:115258681 505 47,52 Epidermal_nevus: Pathogenic PAT 5x as VUS VUS
555 NRAS NM_002524.4 c.101C>T 2 p.Pro34Leu chr1:115258681 495 44,85 Epidermal_nevus: Pathogenic PAT 5x as VUS VUS
556 RAF1 NM_002880.3 c.781C>T 7 p.Pro261Ser chr3:12645688 321 41,74 rs121434594 Noonan: Pathogenic PAT 15x VLP
557 LZTR1 NM_006767.3 c.356A>G 4 p.Tyr119Cys chr22:21341828 331 41,95 PAT 1x VUS
558 A2ML1 NM_144670.4 c.1492A>T 13 p.Ser498Cys chr12:8998053 360 45,28 BENIGN - VUS
559 RRAS NM_006270.3 c.491A>C 5 p.His164Pro chr19:50139072 155 9,03 BENIGN - VUS
560 KRAS NM_004985.3 c.458A>T 5 p.Asp153Val chr12:25362838 300 47,67 rs104894360 CFC: Pathogenic INCONGRUOUS 13x PAT
561 MAP2K1 NM_002755.3 c.199G>A 2 p.Asp67Asn chr15:66727483 530 51,61 Noonan: Pathogenic PAT 4x CFC VLP
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